A Prospective, Multicenter Analysis of Recurrence‐Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31‐<scp>GEP</scp>
These results are consistent with previous studies that showed the 31-GEP can identify patients at low risk of SLN positivity and recurrence.
Authors
- Brian J. Martin (ORCID: https://orcid.org/0000-0002-7243-4559)
- Richard Essner (ORCID: https://orcid.org/0000-0002-2146-8417)
- Joseph I. Clark (ORCID: https://orcid.org/0000-0002-0455-2625)
- John B. Hamner
- Brenda Sickle‐Santanello
- Oliver J. Wisco (ORCID: https://orcid.org/0000-0002-7813-9999)
- Timothy L. Beard
- Stanley P. L. Leong (ORCID: https://orcid.org/0000-0002-0047-0112)
- Maki Yamamoto (ORCID: https://orcid.org/0000-0003-0613-1354)
- Andrew Ward (ORCID: https://orcid.org/0000-0001-8311-5695)
- Mark Cripe
- Rohit Sharma (ORCID: https://orcid.org/0000-0002-3682-3573)
- J. Michael Guenther
Institutions
- OhioHealth (US)
- Loyola University Medical Center (US)
- University of California, Irvine (US)
- Brown University (US)
- California Pacific Medical Center (US)
- University of Tennessee Medical Center (US)
- St. Elizabeth Healthcare (US)
- Columbus Oncology and Hematology Associates (US)
- Summit Medical Group (United States) (US)
- Saint John's Health Center (US)
- Marshfield Clinic (US)
- University of Tennessee at Knoxville (US)
- University of Colorado Colorado Springs (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/cam4.70839
- Citations
- 4
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Castle Biosciences